-+ 0.00%
-+ 0.00%
-+ 0.00%

ARCUTIS ANNOUNCES PUBLICATION OF POSITIVE LONG-TERM SAFETY AND EFFICACY DATA WITH ZORYVE® (ROFLUMILAST) CREAM 0.05% FOR TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS IN CHILDREN AGES 2–5 IN PEDIATRIC DERMATOLOGY

Reuters·03/10/2026 13:00:02

Please log in to view news